These findings were corroborated in the SPOTLIGHT trial that investigated the efficacy and safety of first-line zolbetuximab plus mFOLFOX6 versus chemotherapy alone in patients with CLDN18.2-positive, HER2-negative advanced or metastatic GC or GEJ adenocarcinoma.112 Zolbetuximab treatment showed a significant reduction in the risk of disease progression or death compared with placebo. Here, ERBB2 is linked to gastric cancer.